Arnau-Vives Miguel A, Almenar Luis, Hervas Isabel, Osa Ana, Martinez-Dolz Luis, Rueda Joaquin, Zorio Esther, Martinez-Ortiz De Urbina Luis, Perez Jose L, Mateo Antonio, Palencia Miguel
Cardiology La Fe University Hospital, Valencia, Spain.
J Heart Lung Transplant. 2004 Jul;23(7):850-6. doi: 10.1016/j.healun.2003.08.005.
To evaluate the pattern of brain natriuretic peptide (BNP) concentration in heart transplant (HT) recipients and its relation to the degree of graft rejection determined by endomyocardial biopsy specimen.
We studied 71 consecutive HT recipients (62 men, 53 +/- 11 years). The patients underwent 383 biopsies. Creatinine and BNP concentrations and hemodynamic parameters were determined along with the degree of graft rejection using endomyocardial biopsy specimens. We considered treatable rejection as International Society for Heart and Lung Transplantation Grade >or=2 in the first 90 days and >or=3A thereafter. We included a control group of 36 healthy individuals.
Brain natriuretic peptide concentration was significantly greater among HT recipients (264 +/- 318 pg/ml) than in controls (17 +/- 16 pg/ml). In the first 90 days, BNP concentration was significantly greater among the patients with graft rejection (510 +/- 470, n = 84, vs 278 +/- 255, n = 87; p < 0.0001), although the corresponding discriminatory capacity was small. After the first 90 days, BNP values were similar in patients with and without graft rejection (170 +/- 297, n = 17, vs 142 +/- 203, n = 195; p = not significant). Creatinine concentration increased with time after transplantation and did not correlate with BNP concentration. We observed significant positive correlation between BNP concentration and hemodynamic parameters.
Brain natriuretic peptide concentration remains increased after HT, with stabilization after the 4th month. Brain natriuretic peptide concentrations are slightly greater among patients with treatable rejection, particularly in the first 90 days, although BNP concentration lacks discriminatory capacity to serve as a guide to performing biopsy.
评估心脏移植(HT)受者脑钠肽(BNP)浓度模式及其与通过心内膜心肌活检标本确定的移植排斥程度的关系。
我们研究了71例连续的HT受者(62例男性,年龄53±11岁)。这些患者接受了383次活检。使用心内膜心肌活检标本测定肌酐、BNP浓度、血流动力学参数以及移植排斥程度。我们将可治疗的排斥反应定义为:在最初90天内为国际心肺移植学会分级≥2级,此后为≥3A级。我们纳入了36名健康个体作为对照组。
HT受者的脑钠肽浓度(264±318 pg/ml)显著高于对照组(17±16 pg/ml)。在最初90天内,发生移植排斥的患者BNP浓度显著更高(510±470,n = 84,对比278±255,n = 87;p < 0.0001),尽管相应的鉴别能力较小。在最初90天后,有和没有移植排斥的患者BNP值相似(170±297,n = 17,对比142±203,n = 195;p = 无显著性差异)。肌酐浓度在移植后随时间增加,且与BNP浓度无关。我们观察到BNP浓度与血流动力学参数之间存在显著正相关。
心脏移植后脑钠肽浓度持续升高,在第4个月后趋于稳定。可治疗排斥反应的患者脑钠肽浓度略高,尤其是在最初90天内,尽管BNP浓度缺乏作为活检指导的鉴别能力。